メニュー
Literature - Publication Review

Developing a phenotypic in vitro model for progression of liver steatosis

developing-phenotypic512

Currently, there are no FDA-approved medicines to treat nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), and the complex molecular and genetic mechanisms are not completely understood. To address this, Siobhan Malany, from the Conrad Prebys Center for Chemical Genomics in Florida, US, and colleagues developed a model of hepatic steatosis in functional human induced pluripotent stem cell-derived hepatocytes (hiPSC-Hep). This article discusses some of the study’s main approaches, findings, and potential applications for drug discovery research.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Developing a phenotypic in vitro model for progression of liver steatosis

Download Literature - Publication Review